Q4 Earnings Estimate for Brainsway Issued By HC Wainwright

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Equities researchers at HC Wainwright dropped their Q4 2026 earnings per share (EPS) estimates for shares of Brainsway in a report released on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.13 for the quarter, down from their prior forecast of $0.16. HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Brainsway’s current full-year earnings is $0.30 per share.

Brainsway (NASDAQ:BWAY) last issued its earnings results on Wednesday, May 13th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.07. The company had revenue of $15.53 million during the quarter, compared to analyst estimates of $14.63 million. Brainsway had a return on equity of 12.28% and a net margin of 15.68%.

Several other equities research analysts also recently weighed in on BWAY. Zacks Research downgraded Brainsway from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Wall Street Zen downgraded Brainsway from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings raised Brainsway from a “hold (c)” rating to a “buy (b-)” rating in a research report on Friday, April 24th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Brainsway Stock Performance

Shares of BWAY opened at $15.56 on Thursday. The business’s 50-day moving average is $14.90 and its two-hundred day moving average is $12.06. The company has a market capitalization of $623.02 million, a P/E ratio of 44.46 and a beta of 1.23. Brainsway has a fifty-two week low of $5.01 and a fifty-two week high of $17.35.

Institutional Investors Weigh In On Brainsway

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BWAY. Y.D. More Investments Ltd grew its position in shares of Brainsway by 559.8% during the 4th quarter. Y.D. More Investments Ltd now owns 114,962 shares of the company’s stock valued at $2,187,000 after acquiring an additional 97,537 shares during the period. Zuckerman Investment Group LLC grew its position in shares of Brainsway by 5.3% during the 3rd quarter. Zuckerman Investment Group LLC now owns 40,000 shares of the company’s stock valued at $603,000 after acquiring an additional 2,000 shares during the period. Essex Investment Management Co. LLC grew its position in shares of Brainsway by 3.2% during the 3rd quarter. Essex Investment Management Co. LLC now owns 310,684 shares of the company’s stock valued at $4,682,000 after acquiring an additional 9,744 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Brainsway during the 1st quarter valued at about $232,000. Finally, Bullseye Asset Management LLC acquired a new stake in shares of Brainsway during the 4th quarter valued at about $299,000. 30.11% of the stock is owned by institutional investors and hedge funds.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.